A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2004
11/24/2004	CN1547931A Health sobering-up tea and its making method
11/24/2004	CN1176941C Caspase inhibitors and the use thereof
11/24/2004	CN1176922C 8-quinolinxanthine and 8-isoquinolinxanthine derivs. as PDE 5 inhibitors
11/24/2004	CN1176910C Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
11/24/2004	CN1176908C Process for producing pyridine derivate
11/24/2004	CN1176902C New esters derived from substituted phenyl-cyclohexyl compounds
11/24/2004	CN1176704C Tea for giving-up smoking
11/24/2004	CN1176660C Pharmaceutical application of froctose biphosphate magnesium
11/24/2004	CN1176653C Slow-releasing Anixidan capsule
11/24/2004	CN1176652C Application of demelani in diseases treatment
11/24/2004	CN1176650C Use of balufen in preparation of medicine for treating nicotine depondence
11/24/2004	CN1176649C Inhalant of Shumaputan dry-powder and its preparation method
11/23/2004	US6822120 Sulfone liver X-receptor modulators
11/23/2004	US6822112 Prostaglandin derivatives
11/23/2004	US6822100 Reacting n-sulfonyl-3-vinylindole with ruthenium complex in presence of ethyl diazoacetate and toluene; psychological, sexual, and eating disorders
11/23/2004	US6822097 Compounds and methods of uses
11/23/2004	US6821997 Associated with a decreased presence of cell-specific carbonic anhydrase enzymes; neurodegenerative conditions, dementia, alzheimer's disease; administering compound to increase ca such as forms of zinc
11/23/2004	US6821993 Bioavailable small molecule mimetics of neurotrophic factors that are orally bioavailable and can readily penetrate the blood-brain barrier
11/23/2004	US6821986 Drugs such as (2s)-2-amino-n-(4-anilinophenyl)-5-((imino(2-oxido-2 -oxohydrazino)methyl)amino) pentanamide, used as nitric oxide synthase inhibitors, free radical scavangers or as antioxidants
11/23/2004	US6821985 Administering an nr2b subtype selective n-methyl-d-aspartate (nmda) receptor antagonist with a thrombolytic agent for treating hypoxic or ischemic stroke
11/23/2004	US6821984 Ring fused pyrazole derivatives as CRF antagonists
11/23/2004	US6821981 For therapy of disorders, such as anxiety, aggression and stress, and for the control of various physiological phenomena, such as appetite, thermoregulation, sleep and sexual behavior
11/23/2004	US6821979 Synergistic enhancement of cognitive ability
11/23/2004	US6821976 S-6-hydroxy-buspirone
11/23/2004	US6821973 Compounds
11/23/2004	US6821970 Useful for treating diseases wherein modulation of 5-ht activity is desired; nervous system disorders
11/23/2004	US6821966 Antiinflammatory agents
11/23/2004	US6821964 For prophylaxis and therapy of diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation
11/23/2004	US6821950 Antagonist of a g protein-coupled receptor, which has no agonist activity, and which has a cyclic or constrained acyclic structure
11/23/2004	US6821946 Treating nerve damage; administer insulin like growth factor isoform to human, monitor response of damaged nerves
11/23/2004	US6821753 Replication incompetent herpes viruses for use in gene therapy
11/23/2004	CA2329788C Quinoline derivatives
11/23/2004	CA2326970C Acetylene derivatives as anti-inflammatory/analgesic agents
11/23/2004	CA2231803C Lipid extract having anti-inflammatory activity
11/23/2004	CA2171446C Pseudo- and non-peptide bradykinin receptor antagonists
11/23/2004	CA2164626C Multiple botulinum toxins for treating neuromuscular disorders and conditions
11/23/2004	CA2135768C Indolocarbazole imides and the use thereof
11/23/2004	CA2125288C Serotoninergic ergoline derivatives
11/18/2004	WO2004099782A2 Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39)
11/18/2004	WO2004099395A2 A method for the generation of neural progenitor cells
11/18/2004	WO2004099394A2 A method for efficient transfer of human blastocyst-derived stem cells (hbs cells) from a feeder-supported to a feeder-free culture system
11/18/2004	WO2004099238A1 NOVEL mu-CONOTOXIN PEPTIDES
11/18/2004	WO2004099217A1 Thiadiazine derivatives and use thereof as positive ampa receptor modulators
11/18/2004	WO2004099214A1 Quinoline 3-amino chroman derivatives
11/18/2004	WO2004099213A2 Pyrrolo (1,2-b) pyridazine compounds and their use as crf-1 receptor antagonists
11/18/2004	WO2004099211A1 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
11/18/2004	WO2004099210A1 6-arylmethyl-substituted pyrazolopyrimidines
11/18/2004	WO2004099209A1 Fused pyrimidine derivatives with crf activity
11/18/2004	WO2004099207A1 Microcrystal
11/18/2004	WO2004099206A1 Isoquinoline-3-carboxylic acid amides and pharmaceutical uses thereof
11/18/2004	WO2004099202A1 Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
11/18/2004	WO2004099201A1 Compounds as crf1 receptor antagonists
11/18/2004	WO2004099198A1 Benzoxazinone derivatives having affinity for 5- ht receptors, their preparation and use
11/18/2004	WO2004099191A2 Benzofuranyl-and benzothienyl-piperazinyl quinolines as serotonin reuptake inhib itors
11/18/2004	WO2004099190A1 Novel substituted benzimidazole derivatives
11/18/2004	WO2004099176A1 Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics
11/18/2004	WO2004099161A1 Pyrazinones as crf1 receptor antagonists for the treatment of cns disorders
11/18/2004	WO2004099143A1 Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them
11/18/2004	WO2004099142A1 Hydrobromide salt of benzyl-piperidylmethyl-indanone and its polymorphs
11/18/2004	WO2004098714A1 Methods for treating sinus headache
11/18/2004	WO2004098642A1 Migraine relief composition and methods of using and forming same
11/18/2004	WO2004098639A1 METHOD OF CONTROLLING TGFβ-ORIGIN APOPTOSIS
11/18/2004	WO2004098635A1 Glutamate receptor antagonists as neuroprotectives
11/18/2004	WO2004098631A1 Alzheimer's disease treatment method
11/18/2004	WO2004098622A2 Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic-pituitary-adrenal axis over-activity
11/18/2004	WO2004098614A1 Freeze-dried preparation containing methylcobalamin and process for producing the same
11/18/2004	WO2004098607A1 Pyridinyl acetonitriles
11/18/2004	WO2004098600A1 Positive modulators of nicotinic acetylcholine receptors
11/18/2004	WO2004098591A2 Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
11/18/2004	WO2004098585A1 Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of l-dopa induced movement disorders, dyskinesias, drug addiction, pain and cataract
11/18/2004	WO2004098579A2 Combination of a glycine/nmda antagonist and a tachykinin nk-1 receptor antagonist for use in the treatment of neurodegeneration
11/18/2004	WO2004082573A3 Diagnostics and therapeutics for diseases associated with dopamine receptor d4 (drd4)
11/18/2004	WO2004071381A3 Drugs containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds
11/18/2004	WO2004062686A3 Therapeutic use of modulators of notch
11/18/2004	WO2004060403A3 Aprotinin and anglos as carriers across the blood-brain barrier
11/18/2004	WO2004038406A3 Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 42 (gpr42)
11/18/2004	WO2003090697B1 Chimeric hybrid analgesics
11/18/2004	WO2003080805A3 Kinases and phosphatases
11/18/2004	WO2003038043A3 Combinations of dr5 antibody and other therapeutic agents
11/18/2004	WO2003037913A3 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/18/2004	WO2003037900A3 Pyrazolopyrimidines
11/18/2004	WO2002090499A3 ss-AMYLOID PEPTIDE-BINDING PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME
11/18/2004	WO2002086087A3 Cytokine protein family
11/18/2004	US20040231009 Using variation in sensory organ developmental genes to diagnose and treat nervous system disorders; tissue engineering and gene therapy
11/18/2004	US20040231005 Comprises proteolytic enzymes for use as tools to identify modulators for treatment and prevention of gastrointestinal, cell proliferative and inflammatory diseases
11/18/2004	US20040230257 Enhanced bioavailability of nutrients, pharmaceutical agents, and other bioactive substances through laser resonant homogenization or modification of molecular shape or crystalline form
11/18/2004	US20040230065 Process for the preparation of 5-substituted isobenzofurans
11/18/2004	US20040230064 Novel labeled resiniferatoxin derivatives
11/18/2004	US20040230043 Novel neurotrophic factors
11/18/2004	US20040229956 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
11/18/2004	US20040229943 Analeptic and drug combinations
11/18/2004	US20040229942 Analeptic and antidepressant combinations
11/18/2004	US20040229941 Analeptic and antidepressant combinations
11/18/2004	US20040229940 Analeptic and antidepressant combinations
11/18/2004	US20040229923 Mixing a racemic mixture of enantiomers of pyrrolo[2,3-d]pyrimidine compounds in a solvent, with a resolving compound having a defined stereospecificity, to form a solution and with resolving agent being capable of binding with enantiomers to form a precipitate collecting precipitate and purifying
11/18/2004	US20040229918 Phosphodiesterase 4 inhibitors
11/18/2004	US20040229917 Imidazole derivatives
11/18/2004	US20040229913 Administering 3.0 mg to 10 mg of 1-benzyl-4-(5,6-dimethoxy-1-indanon)2-yl)methylpiperidine or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient
11/18/2004	US20040229907 2-Aminoquinolinecarboxamides: neurokinin receptor ligands
11/18/2004	US20040229897 Aid in cytokine biosynthesis

1 ... 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 ... 1833